Danny is a member of the firm’s Capital Markets Group. His practice focuses on debt and equity financings, going public transactions, mergers and acquisitions and regulatory compliance. He also advises on continuous disclosure obligations and corporate governance matters. Danny represents issuers and investment dealers in a broad range of industries, including cannabis, biotech, E-sports, mining, energy, entertainment and Fintech.
Danny thrives on finding effective and creative solutions to help clients navigate through highly-regulated industries. By carefully considering the needs and goals of his clients, he provides an array of value-added solutions in relation to securities and corporate law matters.
- Represented Cybin Inc. (NEO: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, in the completion of an overnight marketed offering pursuant to a prospectus supplement to Cybin’s short form base shelf prospectus, with aggregate gross proceeds of approximately $34 million.
- Represented Small Pharma Ltd, a U.K.-based neuropharmaceutical company specialized in IP-led development of novel treatments for mental health conditions, in its acquisition by Small Pharma Inc. (formerly Unilock Capital Corp.) (TSXV: DMT) by way of a qualifying transaction and its related brokered and non-brokered private placements for aggregate gross proceeds of $63 million and initial TSX Venture Exchange listing.
- Represented Cybin Inc. in the completion of its reverse takeover of Clarmin Explorations Inc. pursuant to the terms of an amalgamation agreement among Cybin Corp., Clarmin and a wholly-owned subsidiary of the Company as well as a private placement offering of 60 million subscription receipts for aggregate gross proceeds of $45 million.